$GLSI
Greenwich LifeSciences, Inc.

2023 Q1 Form 10-K Financial Statement

#000149315223010284 Filed on March 31, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $413.2K $436.6K $1.565M
YoY Change 25.82% 39.35% 50.67%
% of Gross Profit
Research & Development $1.828M $2.458M $6.476M
YoY Change 10.06% 19.1% 81.93%
% of Gross Profit
Depreciation & Amortization $900.00 $900.00 $3.610K
YoY Change 0.0% 0.0% 0.0%
% of Gross Profit
Operating Expenses $2.241M $2.895M $8.040M
YoY Change 12.66% 21.77% 74.87%
Operating Profit -$2.241M -$8.040M
YoY Change 12.66% 74.87%
Interest Expense $116.2K $104.2K $215.0K
YoY Change 493.36% 531.33% 685.6%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$2.125M -$2.791M -$7.825M
YoY Change 7.88% 18.21% 71.21%
Income Tax
% Of Pretax Income
Net Earnings -$2.125M -$2.791M -$7.825M
YoY Change 7.88% 18.21% 71.21%
Net Earnings / Revenue
Basic Earnings Per Share -$0.17 -$0.61
Diluted Earnings Per Share -$0.17 -$0.22 -$0.61
COMMON SHARES
Basic Shares Outstanding 12.85M shares 12.85M shares
Diluted Shares Outstanding 12.85M shares 12.91M shares

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.91M $13.47M $13.47M
YoY Change -39.67% -50.49% -50.49%
Cash & Equivalents $11.91M $13.47M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $11.91M $13.47M $13.47M
YoY Change -39.67% -50.49% -50.49%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $8.099K $8.999K $9.000K
YoY Change -30.84% -28.66% -28.63%
TOTAL ASSETS
Total Short-Term Assets $11.91M $13.47M $13.47M
Total Long-Term Assets $8.099K $8.999K $9.000K
Total Assets $11.92M $13.48M $13.48M
YoY Change -39.66% -50.48% -50.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $220.9K $220.9K $220.9K
YoY Change 0.0% 0.0% 0.0%
Accrued Expenses $14.73K $42.06K $42.06K
YoY Change -27.51% -74.41% -74.41%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $235.6K $262.9K $262.9K
YoY Change -2.32% -31.74% -31.74%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $235.6K $262.9K $262.9K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $235.6K $262.9K $262.9K
YoY Change -2.32% -31.74% -31.74%
SHAREHOLDERS EQUITY
Retained Earnings -$43.60M -$41.47M
YoY Change 23.26%
Common Stock $55.28M $54.69M
YoY Change -9.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.68M $13.21M $13.21M
YoY Change
Total Liabilities & Shareholders Equity $11.92M $13.48M $13.48M
YoY Change -39.66% -50.48% -50.48%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$2.125M -$2.791M -$7.825M
YoY Change 7.88% 18.21% 71.21%
Depreciation, Depletion And Amortization $900.00 $900.00 $3.610K
YoY Change 0.0% 0.0% 0.0%
Cash From Operating Activities -$1.557M -$2.170M -$6.200M
YoY Change -20.06% -4.16% 44.47%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $7.536M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -$7.536M
YoY Change -100.0% -365.79%
NET CHANGE
Cash From Operating Activities -$1.557M -2.170M -$6.200M
Cash From Investing Activities
Cash From Financing Activities 0.000 -$7.536M
Net Change In Cash -$1.557M -2.170M -$13.74M
YoY Change -79.13% 27.52% 843.35%
FREE CASH FLOW
Cash From Operating Activities -$1.557M -$2.170M -$6.200M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001799788
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Trading Symbol
TradingSymbol
GLSI
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
usd
CY2022 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
usd
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
CY2021 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
usd
CY2022 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-39555
CY2022 dei Entity Registrant Name
EntityRegistrantName
GREENWICH LIFESCIENCES, INC.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-5473709
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
3992 Bluebonnet Dr.
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Building 14
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Stafford
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77477
CY2022 dei City Area Code
CityAreaCode
(832)
CY2022 dei Local Phone Number
LocalPhoneNumber
819-3232
CY2022 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2022 dei Trading Symbol
TradingSymbol
GLSI
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
49174372 usd
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12848165 shares
CY2022 dei Auditor Firm
AuditorFirmId
206
CY2022 dei Auditor Name
AuditorName
MaloneBailey, LLP
CY2022 dei Auditor Location
AuditorLocation
Houston, Texas
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13468026 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27204269 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
9003 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
12615 usd
CY2022Q4 us-gaap Assets
Assets
13477029 usd
CY2021Q4 us-gaap Assets
Assets
27216884 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
220845 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
220845 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
42060 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
164327 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
262905 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
385172 usd
CY2022Q4 us-gaap Liabilities
Liabilities
262905 usd
CY2021Q4 us-gaap Liabilities
Liabilities
385172 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12848165 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12848165 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13147829 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13147829 shares
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
12848 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
13148 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
54674042 usd
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
60466093 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-41472766 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-33647529 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
13214124 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
26831712 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13477029 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
27216884 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6475668 usd
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3559515 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1564586 usd
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1038428 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
8040254 usd
CY2021 us-gaap Operating Expenses
OperatingExpenses
4597943 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-8040254 usd
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-4597943 usd
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
215017 usd
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
27367 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-7825237 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-4570576 usd
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
CY2022 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
12913848 shares
CY2021 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
12944134 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
27631110 usd
CY2021 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
660582 usd
CY2021 GLSI Exercise Of Common Stock From Green Shoe Of Followon Offering Net Of Offering Costs
ExerciseOfCommonStockFromGreenShoeOfFollowonOfferingNetOfOfferingCosts
2548000 usd
CY2021 GLSI Issuance Of Common Stock Through Partial Exercise Of Underwriter Warrants
IssuanceOfCommonStockThroughPartialExerciseOfUnderwriterWarrants
562596 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-4570576 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
26831712 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
26831712 usd
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1743865 usd
CY2022 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
7536216 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-7825237 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
13214124 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
13214124 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-7825237 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-4570576 usd
CY2022 us-gaap Adjustment For Amortization
AdjustmentForAmortization
3612 usd
CY2021 us-gaap Adjustment For Amortization
AdjustmentForAmortization
3612 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
1743865 usd
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
660582 usd
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-526732 usd
CY2021 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
36606 usd
CY2022 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-122267 usd
CY2021 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
104960 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6200027 usd
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4291548 usd
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3110596 usd
CY2022 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
7536216 usd
CY2021 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
-275154 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-7536216 usd
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2835442 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13736243 usd
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1456106 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
27204269 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28660375 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13468026 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
27204269 usd
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_848_eus-gaap--UseOfEstimates_zOE55hSXGQhi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zvNkHdFX02na">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in its financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022 us-gaap Payments For Rent
PaymentsForRent
2555 usd
CY2022 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
the underlying lease expires in May of 2024 .
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
42060 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
164327 usd
CY2020 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
360000 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3137364 usd
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
1860276 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
3137364 usd
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1860276 usd
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
14900000 usd
CY2022 GLSI Operating Loss Carryforward Expiration Date
OperatingLossCarryforwardExpirationDate
2037
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
220845 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
220845 usd
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
893181 shares
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
673017 shares
CY2022Q4 us-gaap Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased
519828 shares
CY2022Q4 us-gaap Stock Repurchase Program Remaining Authorized Repurchase Amount1
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
7536216 usd
CY2021Q4 GLSI Issuance Of Common Stock Through Partial Exercise Of Underwriter Warrants
IssuanceOfCommonStockThroughPartialExerciseOfUnderwriterWarrants
562596 usd
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
161644 usd
CY2022Q4 GLSI Closing Share Price
ClosingSharePrice
15.20 shares
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
20174 shares
CY2022 GLSI Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInValue
9512356 usd
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1248496 usd
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1248496 usd
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
8263860 usd

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
glsi-20221231_lab.xml Edgar Link unprocessable
0001493152-23-010284-index-headers.html Edgar Link pending
0001493152-23-010284-index.html Edgar Link pending
0001493152-23-010284.txt Edgar Link pending
0001493152-23-010284-xbrl.zip Edgar Link pending
ex23-1.htm Edgar Link pending
ex23-1_001.jpg Edgar Link pending
ex23-1_002.jpg Edgar Link pending
ex23-1_003.jpg Edgar Link pending
ex31-1.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-k.htm Edgar Link pending
form10-k_001.jpg Edgar Link pending
form10-k_002.jpg Edgar Link pending
form10-k_003.jpg Edgar Link pending
form10-k_004.jpg Edgar Link pending
form10-k_005.jpg Edgar Link pending
form10-k_006.jpg Edgar Link pending
form10-k_007.jpg Edgar Link pending
glsi-20221231.xsd Edgar Link pending
glsi-20221231_cal.xml Edgar Link unprocessable
glsi-20221231_def.xml Edgar Link unprocessable
form10-k_htm.xml Edgar Link completed
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
glsi-20221231_pre.xml Edgar Link unprocessable